• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

THE RAPEUTIC ANGIOGENESIS FOR ISCHEMIC HEART DISEASE

Research Project

Project/Area Number 11670709
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Circulatory organs internal medicine
Research InstitutionTEIKYO UNIVERSITY

Principal Investigator

TAKESHITA Satoshi  TEIKYO UNIVERSITY SCHOOL OF MEDICINE, DEPARTMENT OF MEDICINE, ASSOCIATE PROFESSOR, 医学部, 助教授 (90271288)

Project Period (FY) 1999 – 2001
Project Status Completed (Fiscal Year 2001)
Budget Amount *help
¥3,600,000 (Direct Cost: ¥3,600,000)
Fiscal Year 2001: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2000: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1999: ¥1,600,000 (Direct Cost: ¥1,600,000)
Keywordsangiogenesis / collaterals / ischemia
Research Abstract

Background : Impaired microvessel development occurs in spontaneously hypertensive rats (SHR) and in patients with essential hypertension. The purpose of this study was to determine whether collateral development is impaired in SHR, and to what extent it is modified by angiotensin-converting enzyme (ACE) inhibition.
Methods and Results : Ischemia was induced in the hindlimb of SHR by excision of the femoral artery, after which the animals were randomly assigned to receive low-dose perindopril (0.2 mg/kg/day), high-dose perindopril (2.0 mg/kg/day), or vehicle for 3 weeks. Normotensive Wistar-Kyoto rats (WKY) with femoral artery excision served as a control group. Collateral development was significantly impaired at 4 weeks in SHR versus WKY based on a reduced hindlimb perfusion ratio by laser Doppler imaging (0.86 ± 0.08 versus 1.03 ± 0.09, P < 0.05), and a lower capillary density (364.5 + 43.0 versus 463.8 ± 63.0 /mm^2, P < 0.05). Perindopril administration significantly augmented hindlimb perfusion (low dose : 1.06 ± 0.15 ; high dose : 1.05 ± 0.12, P < 0.05 for both) as well as capillary density (low dose : 494.3 ± 69.8 /mm^2 ; high dose : 543.9 ± 76.9 /mm^2, P < 0.005 for both) in SHR. Conclusions : These findings indicate that collateral development is impaired in SHR and that this impairment can be reversed by ACE inhibition. The angiogenic properties of an ACE inhibitor may benefit patients with essential hypertension presenting with lower limb vascular insufficiency.

Report

(4 results)
  • 2001 Annual Research Report   Final Research Report Summary
  • 2000 Annual Research Report
  • 1999 Annual Research Report
  • Research Products

    (6 results)

All Other

All Publications (6 results)

  • [Publications] Satoshi Takeshita: "Angiotensin-conventing enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensius rats"Cardiovascular Research. 52. 314-320 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Takeshita S. et al.: "Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats"Cardiovascular Research. 2. 14-320 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Satoshi Takeshita: "Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats"Cardiovascular Research. 52. 314-320 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] 竹下聡: "内皮細胞増殖因子VEGFによる血管新生療法"内科. 85. 886-892 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] 竹下聡: "VEGFを用いた血管新生療法"動脈硬化. 27. 63-67 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] 竹下聡: "虚血性下肢疾患の遺伝子治療"血管医学. 1. 125-131 (2000)

    • Related Report
      2000 Annual Research Report

URL: 

Published: 1999-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi